[1]段宗宝,肖三法,罗惠群.环磷酰胺联合氢氯噻嗪治疗2型糖尿病肾病的临床研究[J].医学信息,2021,34(23):159-161.[doi:10.3969/j.issn.1006-1959.2021.23.048]
　DUAN Zong-bao,XIAO San-fa,LUO Hui-qun.Clinical Study of Cyclophosphamide Combined with Hydrochlorothiazide in the Treatment of Type 2 Diabetic Nephropathy[J].Medical Information,2021,34(23):159-161.[doi:10.3969/j.issn.1006-1959.2021.23.048]
点击复制

环磷酰胺联合氢氯噻嗪治疗2型糖尿病肾病的临床研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年23期
页码:
159-161
栏目:
药物与临床
出版日期:
2021-12-01

文章信息/Info

Title:
Clinical Study of Cyclophosphamide Combined with Hydrochlorothiazide in the Treatment of Type 2 Diabetic Nephropathy
文章编号:
1006-1959（2021）23-0159-03
作者:
段宗宝; 肖三法; 罗惠群
（于都县人民医院肾内科，江西 于都 342300）
Author(s):
DUAN Zong-bao; XIAO San-fa; LUO Hui-qun
(Department of Nephrology,Yudu County People’s Hospital,Yudu 342300,Jiangxi,China)
关键词:
2型糖尿病肾病; 环磷酰胺; 氢氯噻嗪; 同型半胱氨酸; 尿素氮; 胱抑素C
Keywords:
Type 2 diabetic nephropathy; Cyclophosphamide; Hydrochlorothiazide; Homocysteine; Urea nitrogen; Cystatin C
分类号:
R587.2
DOI:
10.3969/j.issn.1006-1959.2021.23.048
文献标志码:
A
摘要:
目的 研究环磷酰胺联合氢氯噻嗪治疗2型糖尿病肾病的应用效果。方法 选取2020年5月-2021年5月于都县人民医院收治的60例2型糖尿病肾病患者作为研究对象，按照随机数字表法分为对照组与观察组，各30例。对照组给予氢氯噻嗪治疗，观察组给予环磷酰胺联合氢氯噻嗪治疗，比较两组治疗效果、肾功能指标[尿白蛋白排泄率（UAER）、血清β2微球蛋白（β2-MG）、血尿素氮（BUN）]、血清同型半胱氨酸（Hcy）、胱抑素C（Cys C）、N末端B型利钠肽原（NT-proBNP）及不良反应发生情况。结果 观察组治疗总有效率为93.33%，高于对照组的80.00%（P＜0.05）。两组治疗后UAER、β2-MG、BUN水平均低于治疗前，且观察组低于对照组（P＜0.05）。两组治疗后Hcy、Cys C、NT-proBNP水平均低于治疗前，且观察组低于对照组（P＜0.05）。两组不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论 环磷酰胺联合氢氯噻嗪治疗2型糖尿病肾病疗效确切，可改善患者肾功能，调节炎症反应及免疫反应，且联合用药不增加不良反应发生几率。
Abstract:
Objective To study the application effect of cyclophosphamide combined with hydrochlorothiazide in the treatment of type 2 diabetic nephropathy.Methods A total of 60 patients with type 2 diabetic nephropathy admitted to Yudu County People’s Hospital from May 2020 to May 2021 were selected as the study subjects. They were divided into control group and observation group according to the random number table method, with 30 cases in each group. The control group was treated with hydrochlorothiazide, while the observation group was treated with cyclophosphamide combined with hydrochlorothiazide. The therapeutic effect, renal function indexes [urinary albumin excretion rate (UAER), serum β2 microglobulin (β2-MG), blood urea nitrogen (BUN)], serum homocysteine (Hcy), cystatin C (Cys C), N-terminal B-type natriuretic peptide (NT-proBNP) and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 93.33%, which was higher than 80.00% of the control group (P<0.05). After treatment, the levels of UAER, β2-MG and BUN in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). After treatment, the levels of Hcy, Cys C and NT-proBNP in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion Cyclophosphamide combined with hydrochlorothiazide is effective in the treatment of type 2 diabetic nephropathy, which can improve renal function, regulate inflammatory response and immune response, and does not increase the incidence of adverse reactions.

参考文献/References:

[1]苏勇,周惠芳,赵钰洁.社区2型糖尿病血糖控制现状调查及发生糖尿病肾病的影响因素分析[J].中国处方药,2021,19(8):155-157.[2]Xie H,Li C,Wen Y,et al.Association of diabetes with failure to achieve complete remission of idiopathic membranous nephropathy[J].Int Urol Nephrol,2020,52(2):337-342.[3]张扬,于静波.联合检测血清胱抑素C、糖化血红蛋白和尿微量尿白蛋白/肌酐在2型糖尿病早期肾损伤诊断价值[J].中国现代药物应用,2021,15(10):106-108.[4]陶志虎,陈家和,李小健,等.地塞米松联合环磷酰胺治疗中老年2型糖尿病合并特发性膜性肾病患者的临床疗效分析[J].中国全科医学,2021,24(17):2169-2173.[5]李庆,方明明.环磷酰胺联合双嘧达莫治疗NS的临床效果及血清补体C1q的表达变化[J].中国中西医结合肾病杂志,2020,21(12):1090-1092.[6]沈宏.免疫抑制剂(环磷酰胺)联合醋酸泼尼松片治疗成人复发性微小病变性肾病综合征患者临床研究[J].中国医学工程,2020,28(5):87-89.[7]张俊清,苏白海,张捷,等.糖尿病肾脏疾病早期预测与诊断专家共识[J].中华内科杂志,2021,60(6):522-532.[8]Li GX,Jiao XH,Cheng XB.Correlations between blood uric acid and the incidence and progression of type 2 diabetes nephropathy[J].Eur Rev Med Pharmacol Sci,2018,22(2):506-511.[9]肖梦瑶,杨迎,刘松梅.2型糖尿病肾病的临床生化指标变化特征和危险因素分析[J].国际检验医学杂志,2021,42(14):1671-1674,1678.[10]Li GX,Jiao XH,Cheng XB.Correlations between blood uric acid and the incidence and progression of type 2 diabetes nephropathy[J].Eur Rev Med Pharmacol Sci,2018,22(2):506-511.[11]张素明,叶丽萍,程卫,等.非布司他联合氢氯噻嗪治疗慢性肾脏病的疗效及对血清Cys-C NT-proBNP的影响[J].河北医学,2020,26(5):763-766.[12]谢怀娅,李超,文煜冰,等.钙调磷酸酶抑制剂和环磷酰胺对2型糖尿病患者中特发性膜性肾病的疗效和预后比较[J].协和医学杂志,2020,11(3):296-300.[13]万青松,谢红萍,杨波.安体舒通联合氢氯噻嗪对2型糖尿病肾病蛋白尿的影响[J].中国现代医学杂志,2015,25(5):57-60.[14]王红华.低分子肝素联合激素、环磷酰胺治疗难治性肾病综合征疗效分析[J].深圳中西医结合杂志,2017,27(5):140-141.[15]Kim Y,Lim JH,Kim MY,et al.The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes[J].J Am Soc Nephrol,2018,29(4):1108-1127.[16]毛文丽,杜琳娜,张真真,等.他克莫司或环磷酰胺联合糖皮质激素治疗特发性膜性肾病的疗效比较[J].临床肾脏病杂志,2018,18(12):756-760.

相似文献/References:

[1]朱津津.Hcy、BNP检测在2型糖尿病肾病早期诊断中的价值分析[J].医学信息,2018,31(03):163.[doi:10.3969/j.issn.1006-1959.2018.03.060]
　ZHU Jin-jin.The Value of Hcy and BNP in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Medical Information,2018,31(23):163.[doi:10.3969/j.issn.1006-1959.2018.03.060]
[2]黄秉文.中美两种2型糖尿病肾病诊断标准中疾病进展及预后因素对比[J].医学信息,2018,31(22):68.[doi:10.3969/j.issn.1006-1959.2018.22.019]
　HUANG Bing-wen.Comparison of Disease Progression and Prognostic Factors in Two Diagnostic Criteria for Type 2 Diabetic Nephropathy in China and the United States[J].Medical Information,2018,31(23):68.[doi:10.3969/j.issn.1006-1959.2018.22.019]
[3]陈晓霞,唐 勇,胡 庆,等.吗替麦考酚酯联合糖皮质激素治疗特发性膜性肾病的疗效观察[J].医学信息,2018,31(22):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
　CHEN Xiao-xia,TANG Yong,HU Qing,et al.Therapeutic Effect of Mycophenolate Mofetil Combined with Glucocorticoid on Idiopathic Membranous Nephropathy[J].Medical Information,2018,31(23):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
[4]王 健,宁 莉,汪国平.甲泼尼龙联合羟基脲治疗原发性膜性肾病的疗效[J].医学信息,2020,33(01):137.[doi:10.3969/j.issn.1006-1959.2020.01.043]
　WANG Jian,NING Li,WANG Guo-ping.Effect of Methylprednisolone Combined with Hydroxyurea in the Treatment of Primary Membranous Nephropathy[J].Medical Information,2020,33(23):137.[doi:10.3969/j.issn.1006-1959.2020.01.043]
[5]赵海莲.血尿酸水平与2型糖尿病肾病患者肾脏损害的相关性分析[J].医学信息,2020,33(06):93.[doi:10.3969/j.issn.1006-1959.2020.06.027]
　ZHAO Hai-lian.Correlation Between Serum Uric Acid Level and Renal Damage in Patients with Type 2 Diabetic Nephropathy[J].Medical Information,2020,33(23):93.[doi:10.3969/j.issn.1006-1959.2020.06.027]
[6]阎 丽,宋 迎.甲状腺激素与不同阶段2型糖尿病肾病的相关性研究[J].医学信息,2022,35(19):155.[doi:10.3969/j.issn.1006-1959.2022.19.045]
　YAN Li,SONG Ying.Study on the Correlation Between Thyroid Hormone and Different Stages of Type 2 Diabetic Nephropathy[J].Medical Information,2022,35(23):155.[doi:10.3969/j.issn.1006-1959.2022.19.045]
[7]付彩雯,吴 艳.FGF23/Klotho在2型糖尿病肾病和骨质疏松共病中的研究现状[J].医学信息,2024,37(03):176.[doi:10.3969/j.issn.1006-1959.2024.03.037]
　FU Cai-wen,WU Yan.Research Status of FGF23/Klotho in the co-morbidities of Type 2 Diabetic Nephropathy and Osteoporosis[J].Medical Information,2024,37(23):176.[doi:10.3969/j.issn.1006-1959.2024.03.037]

更新日期/Last Update: 1900-01-01